Jürgen Rotzler, Head Products & Manufacturing, Solvias and Rainer Wardenga Business Development Enzymicals
Year 2021 closed with the announcement of a non-exclusive
Year 2021 closed with the announcement of a non-exclusive
For any industry involved in chemical manufacture, the development stage of the process is arguably one of the most significant aspects to get right. Development contributes significantly to both financial and time costs, with over two-thirds of the overall expenditure in drug development accounted for in this stage. One approach to lowering development costs is the introduction of a catalytic step or steps, which can provide alternative and effective ways to access your target compounds quicker. Although catalysts can benefit your product development, they can be a hindrance too. Here we examine what happens if you are unable to obtain commercial scale quantities of your optimal catalyst, and possible solutions to get you back on track.
BASF Process Catalysts: We enable sustainability How BASF GREEn precious metal powder catalysts
In the definition of a carbon-neutral energy system and chemical production, the use of hydrogen plays a pivotal role. However, considering the risks associated with its storage and transport under cryogenic conditions and/or at high pressure, the employment of low pressures alternatives is urgent. LOHCs represents a safe and efficient option. This contribution will discuss the use of LOHCs as energy and hydrogen carriers as well as their application in biomass valorization reactions to produce value-added compounds. In this context, the attention will focus on formic acid and small alcohols that are a renewable H-source promising in relevant chemical transformations.
This note (parts 1 and 2) suggests learning from real world examples of value pricing for products and services. It is important to realize that they are the outcome of many years of trying and failing and trying again. An approach in 4 major steps is recommended:
The process starts with your belief that you (can) create real value for your customers. The challenge is that what you think the value is may, not be (fully) correct. So, you need to be a little schizophrenic about this. On the one hand fully convinced and driven that you can bring superior value, but at the same time open and self-critical to want to learn what your customer really needs.
Purolite® Healthcare & Life Sciences has over 40 years of manufacturing expertise and
Dear Readers, As new member of the Scientific Advisory Board I am happy to
Drug shortage and inaccessibility, stemming from exorbitant pharmaceutical drug prices, is only but a fraction of the many factors affecting global health. Most recently, the world was reminded of the role of pandemics in fast tracking the above-mentioned problem. A potentially sustainable solution would entail establishing cost effective and efficient local drug manufacture capacity in different regions. Using the HIV/AIDS epidemic as a case example, efforts by various research groups towards this goal are presented herein.
The pharmaceutical supply chain has been ripe for innovation for quite some time, and the pandemic has further highlighted the need to look at ways to make processes more efficient while increasing transparency and increasing data security. Blockchain is an open, distributed ledger that can efficiently record transactions between two parties in a verifiable and permanent way. Since blockchains are decentralized, distributed, transparent, and immutable, they not only easily solve the issue of counterfeit medicines but can address issues around advanced therapeutic medicinal products (ATMP) tracking.
Specific immunotherapy (SIT) is the first-choice treatment for allergic respiratory diseases. Over the years, the literature has demonstrated that the focus of specific allergen immunotherapy has always been on the search for a safe, easy to use treatment to ensure good patient compliance. The COVID-19 pandemic has severely put many treatment plans to the test but, in the immunotherapy sector, it has been and is still possible to adopt safe treatments that allow them to be continued even during the course of emergency vaccinations, like that of COVID-19.